Immunohistochemical analysis of <i>cfh−/−</i> mice retinae of after the therapeutic regime.

<p>Aβ (4G8+, red) and activated complement C3 (detected with clone 2/11+, #HM1065, Hycult Biotech., <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0065518#pone-0065518-t003" target="_blank">Table 3</a>, green), cross reactivity to retinal sections at 9 months, (after 3 months dosing): (A) negative control (PBS treated), 6F6, at 60 µg dose (B) and 600 µg dose (C). Scalebar = 25 µm), PR = phototreceptors/outer segments, RPE = retinal pigment epithelium, CHO = choroid, DAPI = 4',6-diamidino-2-phenylindole. Left hand panel (A), (B), (C) is stained with DAPI, right hand panel (A), (B), (C), is without DAPI staining. Aβ (D), and activated complement C3, (E), deposition in the RPE/Bruch’s membrane of <i>cfh−/−</i> mice, are plotted as differences from vehicle control with 95% confidence intervals (CI) after therapeutic treatment. Data in graphs (D) and (E) show data at an intermediate time point, after 7 months of age (7MO), 1 month (+4w) after treatment as well as at the end of the regime at 9 months of age (9MO), 3 months (+12w) after treatment. Data in graphs (D) and (E) also shows wild type (WT) mice treated with 6F6 (WT6F6) after 7 months of age (7MO), 1 month (+4w) after treatment. Mice dosed with 6F6 show a dose dependent significant reduction, (asterisks, see text for levels of significance), in Aβ deposition at 60 µg and 600 µg and in activated C3 deposition at 600 µg compared compared to those treated with vehicle, (D) at 9 months of age (9MO), 3 months (+12w) after treatment.